Vtv Therapeutics Stock Price, News & Analysis

vTv Therapeutics has signed a licensing agreement with Anteris Bio for its Nrf2 activator compound, HPP971, aimed at renal disease treatment. Anteris will pay vTv $2 million upfront and may provide up to $151 million in future milestones, along with royalties on sales. HPP971, which has completed two Phase 1 studies, will be renamed ANT-401 and may address chronic kidney disease (CKD), affecting 700 million globally. vTv continues to seek development opportunities for its other Nrf2 compounds.

vTv Therapeutics Inc. (Nasdaq: VTVT) has entered a $47 million common stock purchase agreement with Lincoln Park Capital Fund, LLC to support its clinical trials. This financing will facilitate key developments, including the upcoming results from the Elevage Study for Alzheimer’s and diabetes, and studies for TTP399 and HPP737 aimed at treating diabetes and psoriasis, respectively. The agreement allows vTv to sell shares over a 36-month period, and vTv retains the option to terminate it anytime without penalty.

vTv Therapeutics Inc. (Nasdaq:VTVT) reported its Q3 2020 financial results, revealing a net loss of $2.3 million, an improvement from $5.0 million in Q2. Cash reserves dropped to $1.8 million from $6.4 million. The company concluded enrollment in the Elevage Study of azeliragon for Alzheimer's, expecting topline results in December 2020. Plans for further studies of TTP399 are underway, including a mechanistic study and pivotal trials for type 1 diabetes. R&D expenses decreased to $1.8 million, while G&A expenses were $1.1 million, both showing cost management efforts.

vTv Therapeutics Inc. (Nasdaq: VTVT) announced baseline characteristics from the Elevage clinical study, which evaluates azeliragon for mild Alzheimer's disease in patients with type 2 diabetes. The study includes 43 enrolled patients, showing similar characteristics to a previous subgroup from the STEADFAST trial. Preliminary data suggest the potential efficacy of azeliragon, with the company expecting to report topline results in December 2020. The Elevage study aims to confirm prior findings in a 6-month Phase 2 trial before moving to Phase 3.

vTv Therapeutics Inc. (Nasdaq: VTVT) will present at the 13th Clinical Trials on Alzheimer’s Disease Digital Event on November 4, 2020. The presentation will showcase data from the phase 2 Elevage Study of azeliragon, aimed at treating mild-probable Alzheimer’s in patients with type 2 diabetes. Patient enrollment was completed in September 2020, with topline results expected in December 2020. Preliminary analysis reveals statistically significant cognitive improvements in a subgroup of patients treated with azeliragon compared to placebo, suggesting potential efficacy of the treatment.

vTv Therapeutics (Nasdaq: VTVT) announced positive results from the Phase 2 Simplici-T1 study for TTP399, an oral adjunctive therapy for type 1 diabetes (T1D). Data indicated that TTP399 does not raise the risk of diabetic ketoacidosis (DKA) and leads to significant reductions in HbA1c without increasing hypoglycemia risk. These findings support further development of TTP399, with plans for a pivotal study expected by end of 2020. The study was presented at the European Association for the Study of Diabetes Annual Meeting.

vTv Therapeutics has appointed Edward P. Taibi, Executive Vice President at MacAndrews & Forbes, to its Board of Directors, effective August 31, 2020. This strategic move aims to enhance the company's leadership as it pursues its clinical drug development pipeline targeting type 1 diabetes and Alzheimer’s disease. Mr. Taibi brings extensive experience in business leadership and capital markets from his previous roles. MacAndrews has a significant investment history in vTv, impacting its business strategies.

vTv Therapeutics Inc. (Nasdaq: VTVT) reported its second-quarter 2020 financial results, showing significant progress in advancing its TTP399 drug for type 1 diabetes, with upcoming pivotal studies planned by year-end. The firm is also actively enrolling patients for its Alzheimer's treatment study, despite COVID-19 challenges.

Financially, cash reserves increased to $6.4 million, while R&D expenses decreased to $2.5 million. The net loss for the quarter was $5.0 million, an improvement from the previous quarter's $7.2 million loss. Revenue remained negligible, reflecting ongoing developmental focus.

vTv Therapeutics (Nasdaq: VTVT) announced its participation in the 2020 Alzheimer's Association International Conference (AAIC) from July 27-31, 2020. The company will present a poster showcasing analyses from the STEADFAST Study of azeliragon, which examines its effects on cognitive functions in Alzheimer's patients with type 2 diabetes. The presentation is scheduled for July 29, 2020, at 5:00 pm CT. The STEADFAST study consists of two Phase 3 trials investigating azeliragon's safety and efficacy as a treatment for mild Alzheimer's disease.